$AMGN

Robert A. Bradway

Amgen

Chairman & CEO • Since 2012 • Health Care

Also profiled in: Dow Jones, S&P 500

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

53/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: $10.4B → $8.1B (−22.1% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): $4.1B → $7.7B (+88.5% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Nasdaq-100 reputation leaderboard

Overview

Robert A. Bradway is the chairman & ceo of Amgen since 2012. Amgen is a Health Care company, and one of the 100 companies in the Nasdaq-100 — every one of which is profiled on this site.

Leadership

Robert holds the chief executive role at Amgen with the title Chairman & CEO — in post since 2012. This page is the concise leadership record for Amgen in the Nasdaq-100 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $AMGN
CEO since: 2012
Index: Nasdaq-100 (#8 of 100)